Literature DB >> 1985385

Cardiovascular disease risk profiles.

K M Anderson1, P M Odell, P W Wilson, W B Kannel.   

Abstract

This article presents prediction equations for several cardiovascular disease endpoints, which are based on measurements of several known risk factors. Subjects (n = 5573) were original and offspring subjects in the Framingham Heart Study, aged 30 to 74 years, and initially free of cardiovascular disease. Equations to predict risk for the following were developed: myocardial infarction, coronary heart disease (CHD), death from CHD, stroke, cardiovascular disease, and death from cardiovascular disease. The equations demonstrated the potential importance of controlling multiple risk factors (blood pressure, total cholesterol, high-density lipoprotein cholesterol, smoking, glucose intolerance, and left ventricular hypertrophy) as opposed to focusing on one single risk factor. The parametric model used was seen to have several advantages over existing standard regression models. Unlike logistic regression, it can provide predictions for different lengths of time, and probabilities can be expressed in a more straightforward way than the Cox proportional hazards model.

Entities:  

Mesh:

Year:  1991        PMID: 1985385     DOI: 10.1016/0002-8703(91)90861-b

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  522 in total

1.  Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Authors:  E J Wallis; L E Ramsay; I Ul Haq; P Ghahramani; P R Jackson; K Rowland-Yeo; W W Yeo
Journal:  BMJ       Date:  2000-03-11

2.  Estimating cardiovascular risk for primary prevention: outstanding questions for primary care.

Authors:  J Robson; K Boomla; B Hart; G Feder
Journal:  BMJ       Date:  2000-03-11

3.  Updated New Zealand cardiovascular disease risk-benefit prediction guide.

Authors:  R Jackson
Journal:  BMJ       Date:  2000-03-11

Review 4.  What is the optimal age for starting lipid lowering treatment? A mathematical model.

Authors:  S Ulrich; A D Hingorani; J Martin; P Vallance
Journal:  BMJ       Date:  2000-04-22

5.  Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation.

Authors:  D Kernick
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

6.  Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable.

Authors:  L D Ritchie
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

7.  The primary prevention of coronary heart disease with statins: practice headache or public health?

Authors:  P H Evans
Journal:  Br J Gen Pract       Date:  2000-09       Impact factor: 5.386

8.  Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used.

Authors:  W G Simpson; P Twomey
Journal:  BMJ       Date:  2000-09-09

Review 9.  Cost per millimeter of mercury lowering is a measure of economic value for antihypertensive agents.

Authors:  R S Chen; P Lapuerta
Journal:  Curr Hypertens Rep       Date:  2000-12       Impact factor: 5.369

10.  The impact of multiple predictors on generalist physicians' care of underserved populations.

Authors:  H K Rabinowitz; J J Diamond; J J Veloski; J A Gayle
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.